Search

Displaying results 5941 - 5950 of 10000 in total
  1. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. … The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients.

  2. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  3. Drug

    Heptabarbital

    go.drugbank.com/drugs/DB01354
    Experimental

    Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

  4. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    The rationale for uridine therapy in neuropsychiatric disorders is supported by preclinical and clinical research. … Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients.

  5. Drug

    Archexin

    go.drugbank.com/drugs/DB05971
    Investigational

  6. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  7. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. … It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379].

  8. Drug

    QazCovid-in

    go.drugbank.com/drugs/DB16441
    Investigational

    The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628]. … It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].

  9. Drug

    Volinanserin

    go.drugbank.com/drugs/DB16351
    Investigational

    Volinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study).

  10. Drug

    7-Nitroindazole

    go.drugbank.com/drugs/DB02207
    Experimental

    Categories: Compounds used in a research, industrial, or household setting